The Anne Örtegren Memorial Lecture


Remembering the Influence of Anne Örtegren

The Anne Örtegren Memorial Lecture

For a special event we have a new speaker at the IIMEC13 Conference in London on 1st June 2018.

To give the inaugural Anne Örtegren Memorial Lecture we are very pleased to announce that Professor Theoharis C. Theoharides, Professor of Pharmacology and Internal Medicine at the Director of Molecular Immunopharmacology and Drug Discovery, Department of Immunology at Tufts University School of Medicine, Boston in USA.

Professor Theoharides has been serving as the Clinical Pharmacologist of the Massachusetts Drug Formulary Commission continuously since 1986.

In Greece, he has served on the Supreme Advisory Health Councils of the Ministries of Health and of Social Welfare, as well as on the Board of Directors of the Institute of Pharmaceutical Research and Technology, and he is a member of the International Advisory Committee for the University of Cyprus School of Medicine.

He first showed that mast cells, known for causing allergic reactions, are critical for inflammation, especially in the brain, and are involved in a number of inflammatory conditions that worsen by stress such as allergies, asthma, chronic fatigue syndrome, eczema, fibromyalgia, migraines, mastocytosis, multiple sclerosis, psoriasis, and most recently autism spectrum disorder.

He has also shown that corticotropin-releasing hormone (CRH), neurotensin and substance P, peptides secreted under stress, act together, and with the cytokine IL-33, to trigger mast cells and microglia to secrete inflammatory molecules. These processes are inhibited by the novel flavonoids, luteolin and tetramethoxyluteolin that he has helped formulate in unique dietary supplements and a skin lotion.

He has published over 400 scientific papers (JBC, JACI, JPET, NEJM, Nature, PNAS, Science) and 3 textbooks with 29,887 citations (h-factor 84) and he is in the top 5% of authors most cited in pharmacological and immunological journals. He has received 37 patents and trademarks, including three patents covering the use of luteolin in brain inflammation and autism: US 8,268,365 (09/18/12); US 9,050,275 (06/09/15); US 9,176,146 (11/03/15).

Acting as Advisor, he was instrumental in the development of ibuprofen (Upjohn), Cetirizine (UCB) and Niaspan (Kos). He is also the Scientific Director of Algonot, LLC, as well as President of Theta Biomedical Consulting and Development Co., Inc., of BiomedAdvice, LLC, and of the nonprofit Brain-Gain.org.

He is a member of 15 academies and scientific societies. He was inducted into the Alpha Omega Alpha National Medical Honor Society and the Rare Diseases Hall of Fame.

At Tufts, he served on the Curriculum, Students Promotion, Grievance, Faculty Promotion and Tenure, as well as Strategic Planning Committees.

He received the Tufts Excellence in Teaching ten times, the Tufts Distinguished Faculty Recognition Award twice, the Tufts Alumni Award for Faculty Excellence, Boston Mayor’s Community Award, and the Dr. George Papanicolau Award, as well as Honorary Doctor of Medicine from Athens University and Honorary Doctor of Sciences from Hellenic-American University.

He is “Archon” of the Ecumenical Patriarchate of Constantinople.




Professor Theoharides will also be participating in the 8th International Biomedical Research into ME Colloquium in London - a 2 day event plus evening dinners where the emphasis is on international researchers working together in order to make rapid progress in finding cause(s) and treatment(s) for ME.


Return to Conference News


Last Update 9/02/2018

  

Latest Tweets

Contact Us

  • Invest in ME Research Charity Nr. 1153730

  • Address: PO Box 561 Eastleigh Hampshire SO50 0GQ

  • Phone: 02380 643736 / 07759 349743

  • Email: info @ investinme.org

Follow Us

Help Us